03.06.2013 - GlaxoSmithKline’s multi kinase blocker pazopanib has increased progression free survival in women with advanced ovarian cancer by 5.6 months.
At the ASCO meeting, the British drug major reported that the median time to disease progression under the VEGFR, PDGFR, c-KIT blocker post-surgery and chemotherapy was 17.9 months, compared with 12.3 months in patients receiving placebo. GSK announced that it will file an MAA in the US for pazopanib as first-in-class maintenance therapy after surgery and chemotherapy. In contrast to Europe where Roche’s bevacizumab is approved as maintenance therapy, there is no comparable treatment approved by the FDA.
91% of the 940 patients with advanced epithelial ovarian cancer had stage III/IV disease at diagnosis and no residual disease following surgery. While efficacy was shown, more serious adverse drug effects were observed in the pazopanib group (26%) than in the placebo arm (11%) of the study.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.